scholarly journals Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak

2021 ◽  
Vol 10 (15) ◽  
pp. 3270
Author(s):  
Lorenzo Bertani ◽  
Brigida Barberio ◽  
Domenico Tricò ◽  
Federico Zanzi ◽  
Daria Maniero ◽  
...  
Keyword(s):  
Depression Scale ◽  
Anxiety And Depression ◽  
Disease Relapse ◽  
Hospital Anxiety ◽  
Drug Infusion ◽  
Bowel Diseases ◽  
Risk Of Disease ◽  
Inflammatory Bowel ◽  
Immunomodulatory Therapies ◽  
The Impact

During the coronavirus disease 2019 (COVID-19) pandemic, immunomodulatory therapies and hospital admission were suspected to increase the risk of infection. Nevertheless, patients with inflammatory bowel diseases (IBD) treated with intravenous (i.v.) biologics had to move to hospitals for drug infusion. We investigated the impact of hospitalisation in patients with IBD. We conducted a survey including consecutive IBD patients initially in clinical and biochemical remission treated with biologics at the end of the first lockdown period. Patients underwent the normally scheduled clinical visits, performed at hospital for i.v.-treated patients or at home for patients treated with s.c. drugs. We administered to all patients the Hospital Anxiety and Depression Scale (HADS) questionnaire and other 12 questions, specifically related to COVID-19 and its implications. A total of 189 IBD patients were recruited, 112 (59.3%) treated with i.v. drugs and 77 (40.7%) with s.c. ones. No relapses were recorded in either group (hospitalized vs. non-hospitalized, p = ns), as well as which, COVID-19 infections were not demonstrated in patients in contact with people with suspected symptoms or directly experiencing them. The total HADS score obtained by the sum of all items was also almost identical between groups (37.1 ± 2.8 vs. 37.2 ± 2.8; p = 0.98). In patients treated with i.v. drugs receiving a televisit (n = 17), the rate of satisfaction with telemedicine (58.8%) was significantly lower compared with those treated with s.c. drugs (94.8%; p < 0.0005). Our results suggest that hospitalisation during the COVID-19 outbreak does not increase the risk of COVID-19 infection as well as the risk of IBD relapse; moreover, the similar levels of anxiety in both groups could confirm that there is no need to convert patients from i.v. to s.c. therapy.

scholarly journals Mental health and quality of life in patients with ulcerative colitis

2021 ◽  
pp. 42-46
Author(s):  
V. E. Bandel ◽  
E. I. Mikhailova
Keyword(s):  
Quality Of Life ◽  
Mental Health ◽  
Ulcerative Colitis ◽  
Emotional State ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Hospital Anxiety ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Objective. To study the quality of life (QoL) and psycho-emotional state in patients with different degrees of ulcerative colitis (UC) activity.Materials and methods. The study involved 52 patients with UC and 52 healthy volunteers (HVs). The survey was performed using the questionnaire IBDQ, assessing the quality of life in patients with inflammatory bowel diseases, the Hospital Anxiety and Depression Scale (HADS), and the questionnaire by A.M. Vein.Results. The patients with UC in comparison with the HVs have a lower QoL in the overall score (p < 0.05), a greater severity of psychological problems both according to the anxiety scale (p < 0.05) and to the depression scale (p < 0.05).), and they tend to develop the autonomic dysfunction syndrome more often (p < 0.05).Conclusion. The method of the QoL assessment and psycho-emotional state in patients with UC provides accurate scientifc information about the physical, psychological, emotional and social status of the patients.

scholarly journals Διερεύνηση του πιθανού διαμεσολαβητικού ρόλου των πρωτεϊνών θερμικού shock ανάμεσα στο ψυχοφυσιολογικό στρες και τις οργανικές παθήσεις

2013 ◽  
Author(s):  
Ηλίας Βλάχος
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Depression And Anxiety ◽  
Hospital Anxiety ◽  
Cytoprotective Effect ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Anxiety Levels

Objective – To investigate the hypothesis that depression and anxiety levelscould beassociatedwith theinduction of theantiapoptoticHeatShock Protein70 (HSP70) inthe colon of patients with Inflammatory Bowel Diseases (IBD),namelyulcerativecolitis(UC)andCrohn‟sdisease(CD).Methods- 54 consecutive, hospitalized IBD patients in relapse gave theirinformed consent, filled out psychometric questionnaires [Zung DepressionRatingScale(ZDRS),SpielbergerState-TraitAnxietyInventory(STAIFormXI,IIas a state andas a trait), Hospital Anxiety and Depression Scale (HADS)].Simultaneously, intestinal biopsies were taken to be diagnosed in a blindedmanner by two pathologists. The type and severity of inflammation wereassessedoneachsection withhematoxylin/eosinstaining.Thelocalizationandintensity of expression ofHSP70 expression were studiedimmunohistochemically.Results:31/54patientssufferedfromactiveUC,14fromCDand9wereinremission.InducibleHSP70(HSP70i)wasscarcelydetectableintheintestinalmucosa of UC and CD patients. There was statistically significant correlationbetween depression and anxiety levels and inducible HSP70 in thepolymorphonuclearcells(PMN)ofpatientswithactiveUC.Conclusion: Inducible HSP70 is clearly expressed in PMN cells of IBD patientsand in patients with active UC this finding positively correlates with thedepression and anxiety levels. Given the antiapoptotic, cytoprotective effect ofHSP70onPMNcells and thedestructiverole thatPMNcellsexertonintestinalmucosa of IBD patients, light could be shed on the psychosomatic aspect ofautoimmunityinthesediseases.

Inflammatory bowel disease-related fatigue is correlated with depression and gender

2018 ◽  
Vol 26 (5) ◽  
pp. 508-513 ◽  
Author(s):  
Philip Keightley ◽  
Rebecca E Reay ◽  
Paul Pavli ◽  
Jeffrey CL Looi
Keyword(s):  
Inflammatory Bowel Disease ◽  
Attachment Style ◽  
Functional Assessment ◽  
Bowel Disease ◽  
Depression Scale ◽  
Female Gender ◽  
Anxiety And Depression ◽  
Hospital Anxiety ◽  
Chronic Illness Therapy ◽  
Inflammatory Bowel

Objectives: Fatigue is a common and disabling problem in inflammatory bowel disease. We sought to explore the possible determinants of inflammatory bowel disease-associated fatigue including demographic, psychological and disease variables. Methods: Surveys were distributed to 100 patients undergoing infliximab infusion for inflammatory bowel disease in an infusion lounge, assessing attachment style (Experiences in Close Relationships Revised scale), fatigue (Functional Assessment of Chronic Illness Therapy Fatigue – Fatigue Subscore), and depression and anxiety (Hospital Anxiety and Depression Scale). Disease severity was assessed via file review through an independent gastroenterologist rating (Harvey–Bradshaw Index). Results: There were 67 responses. Depression, as measured by the Hospital Anxiety and Depression Scale, was found to be highly correlated with fatigue (Functional Assessment of Chronic Illness Therapy Fatigue – Fatigue Subscore). Anxiety, insecure attachment, disease severity and female gender were moderately correlated with fatigue. In a hierarchical regression model, depression and female gender emerged as significant predictors of variance in fatigue scores. Conclusions: Depression was the strongest predictor of variance in fatigue scores. Gender as a cause of fatigue in inflammatory bowel disease requires further exploration. Attachment style, however, may still help clinicians to conceptualise help-seeking behaviour and clinician-patient relationships in medically unexplained symptoms.

Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients

2013 ◽  
Vol 20 (1) ◽  
pp. 108-111 ◽  
Author(s):  
Johannis A van Rossum ◽  
Anke Vennegoor ◽  
Lisanne Balk ◽  
Bernard M Uitdehaag ◽  
Chris H Polman ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Jc Virus ◽  
Depression Scale ◽  
Decisional Conflict ◽  
Anxiety And Depression ◽  
Hospital Anxiety ◽  
Analog Scale ◽  
Natalizumab Treatment ◽  
Calculated Risk ◽  
The Impact

The use of natalizumab in multiple sclerosis has been restricted by the risk of progressive multifocal leukoencephalopathy (PML). JC virus carriership, duration of natalizumab treatment and past immunosuppression are known risk factors. This has allowed for calculated risk assessment for individual patients to be implemented. Not much data are available about the effect of JCV carriership on patient willingness to continue natalizumab. Here, we evaluated the impact of JCV seropositivity on safety feelings, anxiety and treatment continuation for patients treated with natalizumab, using a visual analog scale, the Hospital Anxiety and Depression Scale and a decisional conflict scale. Seropositivity led to an elevated anxiety level for PML ( p = 0.004). However, so far only 3% of patients have discontinued natalizumab because of JCV positivity in our cohort.

Course of distress, anxiety, and depression in hematological cancer patients: Association between gender and grade of neoplasm

2013 ◽  
Vol 13 (2) ◽  
pp. 115-123 ◽  
Author(s):  
Cristiane Decat Bergerot ◽  
Karen Lynn Clark ◽  
Alexandre Nonino ◽  
Sarah Waliany ◽  
Marco Murilo Buso ◽  
...  
Keyword(s):  
Significant Interaction ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Hospital Anxiety ◽  
Hematological Cancer ◽  
Physical Problems ◽  
Male Patients ◽  
A Prospective Study ◽  
The Impact ◽  
Over Time

AbstractObjective:The aim of our study was to explore the impact of gender and hematological cancer grade on distress, anxiety, and depression in patients receiving chemotherapy.Methods:A prospective study was done in a cohort of 104 patients with hematological cancer. We employed the (1) Distress Thermometer (DT) and the Problem List (PL) and (2) the Hospital Anxiety and Depression Scale (HADS) for assessments at baseline (T1), the halfway timepoint (T2), and completion of chemotherapy (T3).Results:The proportion of patients experiencing significant distress (DT ≥ 4) decreased from the first to the last timepoint; the proportion experiencing anxiety and depression (as assessed by HADS) also decreased. Specifically, 50% of participants reported significant distress levels, 47.1% anxiety, and 26% depression at T1. At T2, the proportion of patients experiencing distress was reduced by 60.8%, by 76% for anxiety, and by 48.5% for depression; at T3, the reduction was close to 80% for all assessments compared with T1. Emotional and physical problems were most commonly reported. Significant reductions were discovered for distress and problem-related distress levels over time, and a significant interaction was found between gender and practical and physical problems (p < 0.05).Significance of results:Our findings suggest that female patients reported more distress, anxiety, and depression than male patients. Gender differences were related to problem-related distress but not to grade of neoplasm. We observed that, over the course of chemotherapy, the distress levels of patients with hematological cancer decrease over time.

scholarly journals P506 The Impact of Anxiety in Patients With Inflammatory Bowel Diseases Treated With Biologics during COVID Lockdown. A Comparative Study between Hospitalized and non-hospitalized patients

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S487-S488
Author(s):  
L Bertani ◽  
B Barberio ◽  
F Zanzi ◽  
D Maniero ◽  
L Ceccarelli ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Depression Scale ◽  
Stressful Events ◽  
Psychological Status ◽  
Fisher Exact Test ◽  
Increased Risk ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
The Impact ◽  
At Home

Abstract Background The first wave of COVID-19 pandemic management implied to remain at home in order to reduce the spread of the infection. Several patients with inflammatory bowel diseases (IBD) treated with biologics had to go to the hospital to perform intravenous (i.v.) therapies, whereas patients treated with subcutaneous (s.c.) ones could remain at home. Since immumodulatory therapies as well as the access to high-risk places like hopitals have been associated to an increased risk of infections, we have investigated whether patients hospitalized or treated at home showed similar levels of anxiety related to the pandemic situation. Methods We conducted a survey including consecutive IBD patients treated with biologics at three Italian referral centers referring to the first lockdown period. We included consecutive adult patients in clinical and biochemical remission treated with biologics, administered i.v. or s.c. Patients experiencing a disease flare during these months were excluded from the study, in order to avoid potential biases related to disease activity. Patients underwent the normally scheduled clinical visits, performed at home by using phone or video calls for patients treated with s.c. drugs and only in specific cases (i.e. suspected COVID symptoms) for patients treated with i.v. ones. We administered to all patients the Hospital Anxiety and Depression Scale (HADS) questionnaire and other 11 questions, specifically related to COVID and its implications. Group differences in continuous and nominal variables were tested by Kruskal–Wallis test and Fisher exact test, respectively. Results A total of 189 IBD patients were recruited, 112 (59.3%) treated with i.v. drugs and 77 (40.7%) with s.c. ones. The two groups of patients had similar scores in the 14 single items of the HADS questionnaire (p&gt;0.10 for all). The total HADS score obtained by the sum of all items was also almost identical between groups (37.1 ± 2.8 vs 37.2 ± 2.8; p=0.98). In patients treated with i.v. drugs receiving a televisit (n=17), the rates of satisfaction about telemedicine (58.8%) and the lack of in-person care (33.3%) were significantly lower compared with those treated with s.c. drugs (94.8% and 92.2%, respectively; both p&lt;0.0005). Conclusion Our results suggest that there is no need to convert patients from i.v. to s.c. therapy, since the risk of infection as well as of disease relapse due to stressful events are similar in both groups. Moreover, the hospitalization for drug administration does not affect the the psychological status of the patients. Interestingly, patients used to coming to the hospital have more need for in-person contact than patients used to be treated at home, suggesting that the choice of telemedicine should be personalized.

Assessment of the impact of the Hospital Anxiety and Depression Scale on the initiation of treatment in newly diagnosed cancer patients in a safety-net hospital.

2017 ◽  
Vol 35 (31_suppl) ◽  
pp. 250-250
Author(s):  
Daulath Singh ◽  
Annapoorna Singh ◽  
Punita Grover ◽  
Mahathi Indaram ◽  
Nikki Malomo ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Poisson Regression ◽  
Treatment Initiation ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
P Value ◽  
Newly Diagnosed ◽  
Hospital Anxiety ◽  
Poisson Regression Analysis ◽  
The Impact

250 Background: Distress is a universal symptom in oncologic patients which negatively impact the quality of life and survival. It interferes with the ability to cope with the diagnosis and is a risk factor for non-adherence with treatment. The Hospital Anxiety and Depression Scale (HADS), is used at our institution for distress screening. The aim of our study is to assess the impact of distress, measured by the HADS score, on initiation of treatment in newly diagnosed cancer patients. Methods: We conducted a retrospective chart review of patients with a new diagnosis of cancer, between March 1st, 2014 and December 31st, 2015; who had been evaluated for distress at their first oncology clinic visit. We included only patients who were treated with chemotherapy or chemoradiation, with curative intent. Poisson regression analysis was conducted to investigate the relationship between HADS to treatment initiation while including age, sex, race, insurance status, cancer type, and stage as covariates in the model. Results: A total of 101 patients met the inclusion criteria. The mean age was 54 years, 63% were female and 37% were male. The majority were Caucasians (53%), followed by African-Americans (36%). 56% of the population had Medicaid, and 26% had Medicare and private insurance. The most common cancers were – breast (30%), gastrointestinal (20%), gynecologic (15%) and lung (11%). 64% received chemotherapy and 36% were treated with chemoradiation. We grouped patients into 3 categories based on the HADS score – category 1 with score ≤7 (28%), category 2 with score 8-10 (17%) and category 3 with score ≥11 (55%). The median time to treatment initiation was 28 days. Multivariate Poisson regression analysis did not show any correlation between the HADS score and treatment initiation. Subscales analyses showed that higher depression scores correlate with a delay in treatment initiation (p-value 0.01), while the anxiety scores had no influence (p-value 0.57). Conclusions: In our study, the initial total HADS score did not affect the treatment initiation. Interestingly, depression had an influence on the initiation of treatment in newly diagnosed cancer patients.

Sign in / Sign up

Export Citation Format

Share Document